Eighty-six patients with hormone receptor–positive breast cancer who received tamoxifen were classified as poor (PM), intermediate (IM), normal (NM), or ultrarapid (UM) metabolizers according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. The gene discussed is NR4A1; the disease is breast cancer.